|Bid||84.91 x 30000|
|Ask||84.99 x 30000|
|Day's Range||84.43 - 85.15|
|52 Week Range||77.94 - 110.76|
|Beta (5Y Monthly)||0.19|
|PE Ratio (TTM)||41.88|
|Forward Dividend & Yield||2.36 (2.77%)|
|Ex-Dividend Date||Feb 25, 2021|
|1y Target Est||N/A|
n a letter published in the Telegraph, leaders of Britain's biggest hospitality firms also called on prime minister Boris Johnson to stick with the current dates on the roadmap out of lockdown.
AstraZeneca (NASDAQ: AZN) created some drama releasing interim COVID-19 vaccine results just days before the pharma was able to generate final results from the U.S.-based phase 3 study. In this video from Motley Fool Live, recorded on March 29, Fool.com contributors Brian Orelli and Keith Speights discuss the brouhaha, and what it means for AstraZeneca's long-term prospects. Brian Orelli: AstraZeneca reported a final data from its COVID-19 vaccine -- that it went from 79% efficacy at preventing symptomatic COVID-19 for the interim look and then at the final look it was 76%.
The global death toll from the coronavirus-borne illness COVID-19 climbed above 3 million on Saturday and the case tally rose above 140 million, a day after the World Health Organization warned that cases have almost doubled in the last two months, and are now approaching the highest rate seen since the start of the pandemic.